In a recent interview , an official from the Food and Drug Administration (FDA) expressed concern about the costs to the FDA of the priority review voucher program. The director of the Office of New Drugs said he’s worried the additional priority reviews
Read More...
Read the complete post at http://healthaffairs.org/blog/2015/10/28/the-regulatory-burden-of-the-priority-review-voucher-program/
Posted
Oct 28 2015, 11:00 AM
by
Health Affairs Blog